Capricor Therapeutics partners with Nippon Shinyaku for EU/UK distribution of DMD drug deramiocel, with milestone payment up to $715M and profit sharing.

Capricor Therapeutics has partnered with Japan's Nippon Shinyaku Co., Ltd. to commercialize and distribute its drug deramiocel for Duchenne muscular dystrophy in Europe. The agreement includes a $20 million upfront payment, up to $715 million in milestone payments, and a share of product revenue. Nippon Shinyaku will handle sales in the EU and U.K., while Capricor will manage development and manufacturing. The deal aims to support the drug's potential launch in a high-demand market.

September 17, 2024
8 Articles

Further Reading